Advances in the delivery of buprenorphine for opioid dependence

References

• MurrayCJLVosTLozanoRDisability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet2012380 2197 222323245608
   PubMed Web of Science ®Google Scholar
• RuddRAAleshireNZibbellJEGladdenRMIncreases in drug and opioid overdose deaths – United States, 2000–2014MMWR Morb Mortal Wkly Rep20166450 1378 138226720857
   PubMed Web of Science ®Google Scholar
• BahorikALSatreDDKline-SimonAHWeisnerCMCampbellCIAlcohol, cannabis, and opioid use disorders, and disease burden in an integrated health care systemJ Addict Med2017111 3 927610582
   PubMed Web of Science ®Google Scholar
• HserYIMooneyLJSaxonAJHigh mortality among patients with opioid use disorder in a large healthcare systemJ Addict Med Epub2017420
   Web of Science ®Google Scholar
• RuddRASethPDavidFSchollLIncreases in drug and opioid-involved overdose deaths – United States, 2010–2015MMWR Morb Mortal Wkly Rep Epub20161216
   Web of Science ®Google Scholar
• DunlapBCifuASClinical management of opioid use disorderJAMA20163163 338 33927434445
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and QualityBehavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and HealthWashington, DCDepartment of Health and Human Services2015
   Google Scholar
• DugoshKAbrahamASeymourBMcLoydKChalkMFestingerDA systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addictionJ Addict Med2016102 93 10326808307
   PubMed Web of Science ®Google Scholar
• WeissRDPotterJSFiellinDAAdjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trialArch Gen Psychiatry20116812 1238 124622065255
   PubMed Web of Science ®Google Scholar
• NielsenSLaranceBDegenhardtLGowingLKehlerCLintzerisNOpioid agonist treatment for pharmaceutical opioid dependent peopleCochrane Database Syst Rev20165 CD011117
   Google Scholar
• ClarkREBaxterJDAwehGO’ConnellEFisherWHBartonBARisk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment historyJ Subst Abuse Treat201557 75 8025997674
   PubMed Web of Science ®Google Scholar
• AmatoLMinozziSDavoliMVecchiSPsychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependenceCochrane Database Syst Rev201110 CD004147
   PubMed Web of Science ®Google Scholar
• ComptonWMJonesCMBaldwinGTRelationship between non-medical prescription-opioid use and heroin useN Engl J Med2016374 154 16326760086
   PubMed Web of Science ®Google Scholar
• LofwallMRWalshSLA review of buprenorphine diversion and misuse: the current evidence base and experiences from around the worldJ Addict Med201485 315 32625221984
   PubMed Web of Science ®Google Scholar
• OlfsonMWangSIzaMCrystalSBlancoCNational trends in the office-based prescription of schedule II opioidsJ Clin Psychiatry2013749 932 93924107767
   PubMed Web of Science ®Google Scholar
• BarnettMLOlenskiARJenaABOpioid-prescribing patterns of emergency physicians and risk of long-term useN Engl J Med20173767 663 67328199807
   PubMed Web of Science ®Google Scholar
• ShahAHayesCJMartinBCCharacteristics of initial prescription episodes and likelihood of long-term opioid use – United States, 2006–2015MMWR Morb Mortal Wkly Rep201766 265 26928301454
   PubMed Web of Science ®Google Scholar
• KattanJATuazonEPaoneDPublic health detailing – a successful strategy to promote judicious opioid analgesic prescribingAm J Public Health20161068 1430 143827400353
   PubMed Web of Science ®Google Scholar
• DowellDZhangKNoonanRKHockenberryJMMandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death ratesHealth Aff (Millwood)20163510 1876 188327702962
   PubMed Web of Science ®Google Scholar
• PassikSDHaysLEisnerNKirshKLPsychiatric and pain characteristics of prescription drug abusers entering drug rehabilitationJ Pain Palliat Care Pharmacother2006202 5 13
   PubMedGoogle Scholar
• IwanickiJLSevertsonSGMcDanielHAbuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United StatesPLoS One20161112 e016749927936038
   PubMed Web of Science ®Google Scholar
• JohnsonBRichertTDiversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factorsInt J Drug Policy2015262 183 19025465344
   PubMed Web of Science ®Google Scholar
• WinstockARLeaTSheridanJPrevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, AustraliaInt J Drug Policy200819 450 45818359216
   PubMed Web of Science ®Google Scholar
• WinstockARLeaTDiversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, AustraliaSubst Use Misuse201045 240 25220025451
   PubMed Web of Science ®Google Scholar
• YokellMAZallerNDGreenTCRichJDBuprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international reviewCurr Drug Abuse Rev20114 28 4121466501
   PubMedGoogle Scholar
• JohansonCEArfkenCLdi MenzaSSchusterCRDiversion and abuse of buprenorphine: findings from national surveys of treatment patients and physiciansDrug Alcohol Depend20121201–3 190 19521862241
   PubMed Web of Science ®Google Scholar
• FudalaPJJohnsonREDevelopment of opioid formulations with limited diversion and abuse potentialDrug Alcohol Depend200683Suppl 1 S40 S4716564141
   PubMed Web of Science ®Google Scholar
• LaranceBDegenhardtLLintzerisNPost-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosingDrug Alcohol Depend2011118 265 27321565452
   PubMed Web of Science ®Google Scholar
• LintzerisNLeungSYDunlopAJA randomised controlled trial of sublingual buprenorphine–naloxone film versus tablets in the management of opioid dependenceDrug Alcohol Depend2013131 119 12623317685
   PubMed Web of Science ®Google Scholar
• LavonasEJSevertsonSGMartinezEMAbuse and diversion of buprenorphine sublingual tablets and filmJ Subst Abuse Treat2014471 27 3424680219
   PubMed Web of Science ®Google Scholar
• LaranceBLintzerisNAliRThe diversion and injection of a buprenorphine-naloxone soluble film formulationDrug Alcohol Depend2014136 21 2724461476
   PubMed Web of Science ®Google Scholar
• RobinsonSEBuprenorphine: an analgesic with an expanding role in the treatment of opioid addictionCNS Drug Rev200284 377 39012481193
   PubMedGoogle Scholar
• WalshSLPrestonKLStitzerMLConeEJBigelowGEClinical pharmacology of buprenorphine: ceiling effects at high dosesClin Pharmacol Ther1994555 569 5808181201
   PubMed Web of Science ®Google Scholar
• WalshSLEissenbergTThe clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinicDrug Alcohol Depend200370 S13 S27
   PubMed Web of Science ®Google Scholar
• MizoguchiHWuHENaritaMAntagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouseNeuroscience20021153 715 72112435410
   PubMed Web of Science ®Google Scholar
• MizoguchiHSpauldingALeitermannRBuprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouseJ Pharmacol Exp Ther20033061 394 40012721333
   PubMed Web of Science ®Google Scholar
• MattickRPBreenCKimberJDavoliMBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependenceCochrane Database Syst Rev20142 CD002207
   PubMed Web of Science ®Google Scholar
• JohnsonREEissenbergTStitzerMLStrainECLiebsonIABigelowGEA placebo controlled trial of buprenorphine as a treatment for opioid dependenceDrug Alcohol Depend1995401 17 258746920
   PubMed Web of Science ®Google Scholar
• LingWCharuvastraCCollinsJFBuprenorphine maintenance treatment of opiate dependence: a multicenter, randomised clinical trialAddiction1998934 475 4869684386
   PubMed Web of Science ®Google Scholar
• MinozziSAmatoLVecchiSDavoliMKirchmayerUVersterAOral naltrexone maintenance treatment for opioid dependenceCochrane Database Syst Rev20112 CD001333
   PubMed Web of Science ®Google Scholar
• SchottenfeldRSChawarskiMCMazlanMMaintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trialLancet2008371 2192 220018586174
   PubMed Web of Science ®Google Scholar
• BandawarMKandasamyAChandPMurthyPBenegalVAdherence to buprenorphine maintenance treatment in opioid dependence syndrome: a case control studyIndian J Psychol Med2015373 330 33226664083
   PubMedGoogle Scholar
• MokriAChawarskiMCTaherinakhostHSchottenfeldRSMedical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrex-one maintenance treatmentAddiction20161115 874 88226639678
   PubMed Web of Science ®Google Scholar
• LopatkoOVWhiteJMHuberALingWOpioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphineDrug Alcohol Depend200369 317 32212633918
   PubMed Web of Science ®Google Scholar
• KleppnerSRPatelRMcDonoughJCostantiniLCIn vitro and in vivo characterization of a buprenorphine delivery systemJ Pharm Pharmacol200658 295 30216536895
   PubMed Web of Science ®Google Scholar
• NieuwlaatRWilczynskiNNavarroTInterventions for enhancing medication adherenceCochrane Database Syst Rev201411 CD000011
   PubMed Web of Science ®Google Scholar
• ZwebenAPettinatiHMWeissRDRelationship between medication adherence and treatment outcomes: the COMBINE studyAlcohol Clin Exp Res2008329 1661 166918616687
   PubMed Web of Science ®Google Scholar
• CasatiASedefovRPfeiffer-GerschelTMisuse of medicines in the European Union: a systematic review of the literatureEur Addict Res2012185 228 24522572594
   PubMed Web of Science ®Google Scholar
• BoyerEWMcCance-KatzEFMarcusSMethadone and buprenorphine toxicity in childrenAm J Addict2010191 89 9520132125
   PubMed Web of Science ®Google Scholar
• MartinTCRocqueMAAccidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999–2009Curr Drug Saf20116 12 1621047302
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC)Emergency department visits and hospitalizations for buprenorphine ingestion by children – United States, 2010–2011MMWR Morb Mortal Wkly Rep2013623 5623344700
   PubMed Web of Science ®Google Scholar
• BudnitzDSLovegroveMCSapianoMRNotes from the field: pediatric emergency department visits for buprenorphine/naloxone ingestion – United States, 2008–2015MMWR Morb Mortal Wkly Rep20166541 1148 114927764078
   PubMed Web of Science ®Google Scholar
• RitterAJLintzerisNClarkNKutinJJBammerGPanjariMA randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in AustraliaAddiction20039811 1605 161314616187
   PubMed Web of Science ®Google Scholar
• AnglinMDConnerBTAnnonJJLongshoreDLongitudinal effects of LAAM and methadone maintenance on heroin addict behaviorJ Behav Health Serv Res2009362 267 28219023658
   PubMed Web of Science ®Google Scholar
• WolsteinJGastparMFinkbeinerTA randomized, open-label trial comparing methadone and levo-alpha-acetylmethadol (LAAM) in maintenance treatment of opioid addictionPharmacopsychiatry2009421 1 819153939
   PubMed Web of Science ®Google Scholar
• NewcombeDABochnerFWhiteJMSomogyiAAEvaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysisDrug Alcohol Depend2004761 63 7215380290
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services [webpage on the Internet]Orlaam (levomethadyl acetate hydrochloride) Available from: https://wayback.archive-it.org/7993/20170112171230/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm153332.htmAccessed April 4, 2017
   Google Scholar
• MinozziSAmatoLVecchiSDavoliMKirchmayerUVersterAOral naltrexone maintenance treatment for opioid dependenceCochrane Database Syst Rev20061 CD001333
   Google Scholar
• NunesEVRothenbergJLSullivanMABehavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectivenessAm J Drug Alcohol Abuse2006324 503 51717127538
   PubMed Web of Science ®Google Scholar
• BisagaASullivanMAChengWYA placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependenceDrug Alcohol Depend20111191–2 e23 e2921715107
   PubMedGoogle Scholar
• KunøeNLobmaierPNgoHHulseGInjectable and implantable sustained release naltrexone in the treatment of opioid addictionBr J Clin Pharmacol2012772 264 271
   Web of Science ®Google Scholar
• KrupitskyENunesEVLingWIlleperumaAGastfriendDRSilvermanBLInjectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trialLancet20113779776 1506 151321529928
   PubMed Web of Science ®Google Scholar
• CovielloDMCornishJWLynchKGA multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationersSubst Abus2012331 48 5922263713
   PubMed Web of Science ®Google Scholar
• GordonMSKinlockTWVocciFJA phase 4, pilot, open-label study of VIVITROL® (extended-release naltrexone XR-NTX) for prisonersJ Subst Abuse Treat201559 52 5826299956
   PubMed Web of Science ®Google Scholar
• LeeJFriedmannPKinlockTExtended-release naltrexone to prevent opioid relapse in criminal justice offendersN Engl J Med2016374 1232 124227028913
   PubMed Web of Science ®Google Scholar
• HulseGKMorrisNArnold-ReedDTaitRJImproving clinical outcomes in treating heroin dependenceArch Gen Psychiatry20096610 1108 111519805701
   PubMed Web of Science ®Google Scholar
• KrupitskyEZvartauEBlokhinaERandomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependenceArch Gen Psychiatry2012699 973 98122945623
   PubMed Web of Science ®Google Scholar
• DasNGDasSKDevelopment of mucoadhesive dosage forms of buprenorphine for sublingual drug deliveryDrug Deliv2004112 89 9515200007
   PubMed Web of Science ®Google Scholar
• SullivanJGWebsterLNovel buccal film formulation of buprenorphine-naloxone for the maintenance treatment of opioid dependence: a 12-week conversion studyClin Ther2015375 1064 107525823919
   PubMed Web of Science ®Google Scholar
• SigmonSCWongCJNuwayserEChausmerALLiebsonIABigelowGEEvaluation of an injection depot formulation of buprenorphineAddiction200499 1439 144915500597
   PubMed Web of Science ®Google Scholar
• SigmonSCMoodyDENuwayserESBigelowGEAn injection depot formulation of buprenorphine: extended bio-delivery and effectsAddiction20061013 420 43216499515
   PubMed Web of Science ®Google Scholar
• PackhaeuserCBSchniedersJOsterCGKisselTIn situ forming parenteral drug delivery systems: an overviewEur J Pharm Biopharm200458 445 45515296966
   PubMed Web of Science ®Google Scholar
• NasserAFHeidbrederCGomeniRFudalaPJZhengBGreenwaldMKA population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependenceClin Pharmacokinet2014539 813 82425015174
   PubMed Web of Science ®Google Scholar
• NasserAFGreenwaldMKVinceBSustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorderJ Clin Psychopharmacol2016361 18 2626650971
   PubMed Web of Science ®Google Scholar
• LaffontCMGomeniRHeidbrederCJonesJP3rdNasserAFPopulation pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorderJ Clin Pharmacol2016567 806 81526479717
   PubMed Web of Science ®Google Scholar
• Indivior [webpage on the Internet]Indivior announces positive top-line phase 3 pivotal study results for RBP-6000 buprenorphine monthly depot for the treatment of opioid use disorder [press release]8172016 Available from: http://www.indivior.com/investor-news/rbp-6000-phase-3-top-line-results/Accessed May 2, 2017
   Google Scholar
• TibergFJohnssonMDrug delivery applications of non-lamellar liquid crystalline phases and nanoparticlesJ Drug Delivery Sci Technol2011211 101 109
   Web of Science ®Google Scholar
• TibergFJohnssonMJankunecMBarauskasJPhase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositionsChem Lett201241 1090 1092
   Web of Science ®Google Scholar
• Braeburn Pharmaceuticals and Camurus announce positive top-line phase 3 results for long-acting buprenorphine for treatment of opioid addiction [press release]. CAM-2035 [November 14, 2016] Available from: http://mb.cision.com/Main/13456/2125166/591383.pdfAccessed March 4, 2017
   Google Scholar
• LanierRKUmbrichtAHarrisonJANuwayserESBigelowGEEvaluation of a transdermal buprenorphine formulation in opioid detoxificationAddiction2007102 1648 165617854341
   PubMed Web of Science ®Google Scholar
• LanierRKUmbrichtAHarrisonJANuwayserESBigelowGEOpioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluationPsychopharmacology (Berl)2008198 149 15818327673
   PubMed Web of Science ®Google Scholar
• WiegandTJLe LaitMCBucher BartelsonBDartRCGreenJLAnalysis of the abuse and diversion of buprenorphine transdermal delivery systemJ Pain2016176 745 75226996928
   PubMed Web of Science ®Google Scholar
• WhiteJBellJSaundersJBOpen-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependenceDrug Alcohol Depend20091031–2 37 4319403243
   PubMed Web of Science ®Google Scholar
• KuhlmanJJJrLevineBJohnsonREFudalaPJConeEJRelationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphineAddiction199893 549 5599684393
   PubMed Web of Science ®Google Scholar
• ElkaderASprouleBBuprenorphine: clinical pharmacokinetics in the treatment of opioid dependenceClin Pharmacokinet200544 661 68015966752
   PubMed Web of Science ®Google Scholar
• LingWCasadontePBigelowGBuprenorphine implants for treatment of opioid dependence: a randomized controlled trialJAMA201030414 1576 158320940383
   PubMed Web of Science ®Google Scholar
• RosenthalRNLingWCasadontePBuprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxoneAddiction201310812 2141 214923919595
   PubMed Web of Science ®Google Scholar
• O’ConnorPGBuprenorphine implants and opioid dependence – in replyJAMA2011305 253 255
   Web of Science ®Google Scholar
• BasuDKumarVBuprenorphine implants and opioid dependenceJAMA2011305 253 254
   Web of Science ®Google Scholar
• RastegarDABuprenorphine implants and opioid dependenceJAMA2011305 253
   Web of Science ®Google Scholar
• LingWRosenthalRNBeebeKLBuprenorphine implants and opioid dependenceJAMA2011305 254
   Web of Science ®Google Scholar
• RosenthalRNLofwallMRKimSPRO-814 Study GroupEffect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trialJAMA20163163 282 29027434441
   PubMed Web of Science ®Google Scholar
• HserYIEvansEHuangDLong-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trialAddiction20161114 695 70526599131
   PubMed Web of Science ®Google Scholar
• BentzleyBSBarthKSBackSEBookSWDiscontinuation of buprenorphine maintenance therapy: perspectives and outcomesJ Subst Abuse Treat201552 48 5725601365
   PubMed Web of Science ®Google Scholar
• ComptonWMVolkowNDImproving outcomes for persons with opioid use disorders buprenorphine implants to improve adherence and access to careJAMA20163163 277 27927434440
   PubMed Web of Science ®Google Scholar
• MishlenKBarbieriVAMariaASullivanMABisagaAOpioid use following an outpatient detoxification and induction onto XR-NTX: testing the blockade as a predictor of retention in treatmentDrug Alcohol Depend2017171 e146
   Web of Science ®Google Scholar
• HserYIHuangDSaxonAJDistinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine+naloxone and methadoneJ Addict Med2017111 63 6927898496
   PubMed Web of Science ®Google Scholar
• StanosSPBruckenthalPBarkinRLStrategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tamperingMayo Clin Proc2012877 683 69422766088
   PubMed Web of Science ®Google Scholar
• PatelRABucaloLR webpage on the InternetImplantable polymeric device for sustained release of buprenorphineUnited States patent7,736,665United States Patent and Trademark Office2010615 Available from: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7,736,665.PN.&OS=PN/7,736,665&RS=PN/7,736,665Accessed April 10, 2017
   Google Scholar
• US Code of Federal Regulations [webpage on the Internet]. 42 CFR §8.12 Available from: https://ecfr.io/Title-42/se42.1.8_112Accessed February 6, 2017
   Google Scholar
• RemingtonGJAdamsMEDepot neuroleptic therapy: clinical considerationsCan J Psychiatry199540 S5 S117627927
   PubMed Web of Science ®Google Scholar
• WoodyGEPooleSASubramaniumGExtended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trialJAMA200830017 2003 201118984887
   PubMed Web of Science ®Google Scholar
• BaileyGLHermanDSSteinMDPerceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxificationJ Subst Abuse Treat2013453 302 30523786852
   PubMed Web of Science ®Google Scholar
• HillhouseMCanamarCPDoraimaniGThomasCHassonALingWParticipant characteristics and buprenorphine doseAm J Drug Alcohol Abuse2011375 453 45921854290
   PubMed Web of Science ®Google Scholar